A Study Comparing Combination of Encorafenib + Binimetinib as a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis
A Study Comparing Combination of Encorafenib + Binimetinib as a Standard-dose and a High dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis. A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis.
Category & Conditions: Cancer
Medicine: Braftovi (encorafinib) + Mektovi (binimetinib)
ClinicalTrials.gov Identifier (NCT): NCT03911869
Protocol ID: C4221006 (ARRAY-818-201)
PrintDownloadOpen Plain Language Summary Result: Click here